EP1601347A1 - Utilisation de silice ou d'un derive de silice en tant que materiau de sorption - Google Patents

Utilisation de silice ou d'un derive de silice en tant que materiau de sorption

Info

Publication number
EP1601347A1
EP1601347A1 EP04711988A EP04711988A EP1601347A1 EP 1601347 A1 EP1601347 A1 EP 1601347A1 EP 04711988 A EP04711988 A EP 04711988A EP 04711988 A EP04711988 A EP 04711988A EP 1601347 A1 EP1601347 A1 EP 1601347A1
Authority
EP
European Patent Office
Prior art keywords
silica
oil
use according
derivative
tested
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04711988A
Other languages
German (de)
English (en)
Inventor
Per Holm
Tomas Norling
Helle Eliasen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veloxis Pharmaceuticals AS
Original Assignee
Lifecycle Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecycle Pharma AS filed Critical Lifecycle Pharma AS
Publication of EP1601347A1 publication Critical patent/EP1601347A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Definitions

  • the present invention relates to the use of silica or silica derivative in solid form as a sorption material for liquid material or material that has a melting point below about 250
  • silica or silica derivative is suitable in formulation of pharmaceutical, cosmetic and/or foodstuff compositions, especially in those situations where the compositions are presented in solid form although they contain a relatively large amount of oil or an oily-like material.
  • the invention relates to a solid pharmaceutical particulate material or a solid pharmaceutical composition
  • a solid pharmaceutical particulate material or a solid pharmaceutical composition comprising i) an oil or an oily-like material, ii) a sorption material for oils or oily-like materials as defined herein, wherein the concentration of the oil or oily-like material in the particulate material is about
  • compositions comprising one or more active compounds and various excipients.
  • One reason for preparing such pharmaceutical compositions is to manipulate the availability of the active compound after ingestion of the pharmaceutical composition.
  • the active compounds are often incorporated into an agglomerated preparation in order to provide the active compounds in a form that may be pressed into tablets or filled into capsules.
  • agglomerates may also be designed to secure a desired availability of the active compound after ingestion of a pharmaceutical composition containing said granule.
  • One commonly used technique for granulation is a wet granulation, where a mixture of powders including the active compound is mixed with a liquid, usually an aqueous liquid, under mechanical influence for the preparation of granules. Usually the granules prepared by wet granulation are dried before use.
  • Melt agglomeration and controlled agglomeration are techniques for agglomeration of an active compound, essentially performed by melting a pharmaceutical acceptable vehicle such as an oil or an oily-like material, dissolution or dispersion of one or more active compounds in the melted vehicle and deposition of the thus prepared mixture on a particulate material, the filler, and subsequently the particles adhere to each other and form agglomerates.
  • a pharmaceutical acceptable vehicle such as an oil or an oily-like material
  • WO 03/004001 (by the present inventors) is described the novel technique of controlled agglomeration by which it is possible to load a particulate material with a relatively high amount of an oil or an oily-like material.
  • the technique is based on a process that involves spraying of a carrier composition containing the oil or oily-like material onto a particulate material.
  • the process conditions enable the particulate material to be loaded with a relatively high amount of the oil or oily-like material.
  • the process involves heating of the carrier composition and maintaining the temperature of the carrier composition during application.
  • strict temperature control of the spraying equipment is a requirement in order to avoid problems relating to clotting of the spray nozzle etc.
  • silica or silica derivatives have the ability to absorb or adsorb oils or oily-like materials. To the best of the inventors knowledge, this ability has not been recognized or used before in the pharmaceutical field and the present inventors have found that this ability can be utilized in the preparation of compositions having a relatively high content of an oil or an oily-like material and, especially, it is suitable for use in the controlled agglomeration process involving relatively insoluble drug substances.
  • the present inventors have surprisingly found that specific types of silica or silica derivatives have suitable properties with respect to uptake of liquids or melted materials, i.e. materials that have a melting point above ambient temperature. This feature can be used in the development of pharmaceutical formulation such as e.g. within formulations based on agglomeration techniques.
  • the present invention relates to new and useful agglomerated pharmaceutical compositions comprising a silica or silica derivative and a pharmaceutically, prophylactically and/or diagnostically active compound.
  • compositions such as e.g. agglomerated compositions
  • the compositions can contain a high amount of an oil or oily-like material having active compounds dissolved or dispersed therein.
  • compositions for oral ingestion such as tablets or capsules prepared using the agglomerated compositions according to the invention having a higher content of vehicle and/or the active compound can be manufactured.
  • smaller tablets may be prepared with the following improved acceptance by the consumer and a reduced consumption of excipients, tablet additives, coatings etc. for the manufacturer.
  • a higher amount of oil or oily-like material may be incorporated into a pharmaceutical composition in order to improve the bioavailability of the active compound.
  • compositions according to the invention can easily be compressed into tablets.
  • the invention relates to a procedure for the preparation of the agglomerated composition.
  • controlled agglomeration is used for a process for preparing a material where a melt of an oil or an oily-like material optionally comprising an active substance is deposited on a solid composition to enable the formation of an agglomerate.
  • the term is also defined in WO 03/004001 to which reference is made, and which is hereby incorporated by reference in its entirety.
  • agglomerate is used in the usual meaning i.e. a material composed of agglomerated primary particles. It is usually preferred to prepare agglomerates comprising active compounds before these are manufactured into pharmaceutical composition. Agglomerates provide the benefits of less dusting during handling thereof compared with powders, as well as excellent flowability.
  • particle volume size distribution means the distribution of equivalent spherical diameters as determined by laser diffraction at 0.2 bar dispersive pressure in a Sympatec Helos equipment.
  • Median particle size correspondingly, means the median of said particle size distribution.
  • Silica such as silicon dioxide is a well-known compound for pharmaceutical use having a number of known uses.
  • the pharmaceutical use of silicon dioxide has been described in the well recognized "Handbook of Pharmaceutical Excipients, 3 rd ed. 2000, Published by the American Pharmaceutical Association, 2215 Constitution Avenue, NW Washington, DC 20037-2985 USA and the Pharmaceutical Press, 1 Lamberth High Street, London, UK; as adsorbent, anticaking agent; emulsion stabilizer; glidant; suspending agent; tablet disintegrant; thermal stabilizer; viscosity-increasing agent.
  • silicon dioxide Despite of the wide use of silicon dioxide within the pharmaceutical area the use as filler in a melt agglomeration process is new.
  • melt agglomerate having silicon dioxide as filler may be used for the manufacture of pharmaceutical compositions because one would expect that the active compound comprised in said agglomerate would not be released at a sufficiently high rate because the silicon dioxide does not dissolve in the gastrointestinal tract and it may even provide a viscous gel.
  • the present invention relates to the use of a silica or silica derivative, which - when tested as described herein - i) has an oil threshold value of 10% or more, when tested according to the Threshold Test herein, ii) has a bulk density of at least about 15 g/100 ml, and at least one of iii) releases at least 30% of an oil, when tested according to the Release Test herein, and iv) in the form of a tablet has a disintegration time of at the most 1 hour, when tested according to Ph. Eur.
  • the tablet containing about 90% w/w or more of the silica or silica derivative, v) in the form of a tablet has a tablet hardness of at least about 10 N when tested as described herein, as a sorption material for oils or oily-like materials.
  • the material is especially useful as a sorption material for oils or oily-like materials in pharmaceuticals, cosmetics and/or foodstuff.
  • the material is for use as a sorption material for oils or oily-like materials in pharmaceuticals.
  • silica or silica derivative that has the ability to function as a sorption material for oils or oily-like materials is also denoted “oil sorption material”.
  • oil sorption material oil sorption material
  • sorption is used to denote “absorption” as well as “adsorption”. It should be understood that whenever one of the terms is used it is intended to cover the phenomenon absorption as well as adsorption.
  • the Threshold Test gives a measure for how much oil or oily-like material the oil sorption material is able to absorb while retaining suitable flowability properties. It is important that an oil sorption material according to the invention (with or without oil absorbed) has a suitable flowability so that it easily can be admixed with other excipients and/or further processed into compositions without significant problems relating to e.g. adherence to the apparatus involved.
  • the test is described in the Experimental section herein and guidance is given for how the test is carried out.
  • the Threshold Test involves the determination of the flowability of the solid material loaded with different amounts of oil.
  • the oil threshold value normally must exceed 10% and often the oil sorption material has an oil threshold value of at least about 15%, such as, e.g., at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, or at least about 45%.
  • Aeroperl® such as, e.g., Aeroperl® 300
  • Aeroperl® 300 has a very high oil threshold value of about 60%. Accordingly, materials that have an oil threshold value of at least about 50%, such as, e.g., at least about 55% or at least about 60% are specific embodiments of the present invention. The other mandatory requirement is with respect to bulk density.
  • the silica or silica derivative used as an oil sorption material must have a bulk density that is at least about 15 g/100 ml such as, e.g., from about 15 to about 30 g/100 ml, from about 17 to about 28 g/IOOml, from about 19 to about 25 g/100 ml, from about 20 to about 25 g/100 ml, from about 20 to about 23 g/ml such as about 21 g/100 ml.
  • the silica or silica derivative has a tapped density of at least about 20 g/100 ml such as, e.g., at least about 22 g/100 ml, at least about 25 g/100 ml, at least about 26 g/100 ml, at least about 27 g/100 ml, and/or at the most about 40 g/100 ml such as, e.g. at the most about 35 g/100 ml or at the most about 30 g/100 ml.
  • an oil sorption material according to the invention must fulfill at least one further test, namely a release test, a disintegration test and a tablet hardness test.
  • the release test gives a measure of the ability of an oil sorption material to release the oil that is absorbed to the material when contacted with water. This ability is very important especially in those situations where an active substance is contained in the oil or oily-like material. If the oil sorption material is not capable of releasing the oil from the material then there is a major risk that the active substance will only to a minor degree be released from the material. Accordingly, it is envisaged that bioavailability problems relating to e.g. poor absorption etc. will occur in such situations.
  • the requirements for the release test are that the solid pharmaceutical acceptable material - when tested as described herein - ii) releases at least about 30% such as, e.g., at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 60% of an oil.
  • the solid pharmaceutical acceptable material - when tested as described herein - ii) releases at least about 65% such as, e.g., at least about 70%, at least about 75% or at least about 80% of an oil.
  • the second of the tests at least one of which an oil sorption material according to the invention must fulfil is a disintegration test.
  • the test is not performed on the solid material in particular form but on a tablet made of the solid material.
  • a requirement with respect to disintegration is important in order to ensure that the solid material - when included in solid dosage forms - does not impart unwanted properties to the dosage form e.g. leading to unwanted properties with respect to dissolution and bioavailability of the active substance contained in the dosage form.
  • the solid pharmaceutical acceptable material for use according to invention- when tested as described herein iii) in the form of a tablet should have a disintegration time of at the most 1 hour, when tested according to Ph. Eur. Disintegration test, the tablet containing about 90% w/w or more, such as, e.g., about 92.5% w/w or more, about 95% w/w or more, about 97.5% w/w or more or about 100% of the pharmaceutically acceptable material.
  • the solid pharmaceutical acceptable material - when tested as described herein iii) in the form of a tablet has a disintegration time of at the most about 50 min, such as, e.g., at the most about 40 min, at the most about 30 min, at the most about 20 min, at the most about 10 min or at the most about 5 min, when tested according to Ph. Eur. Disintegration test, the tablet containing about 90% w/w or more, such as, e.g., about 92.5% w/w or more, about 95% w/w or more, about 97.5% w/w or more or about 100% of the pharmaceutically acceptable material.
  • the third of the tests at least one of which an oil sorption material according to the invention must fulfil is a tablet hardness test.
  • the test is not performed on the solid material in particular form but on a tablet made of the solid material.
  • the silica or silica derivative does not impart poor tablet hardness to such tablets. According a certain tablet hardness is desirable (but not to such an extent that the disintegration time is impaired).
  • the silica or silica derivative in the form of a tablet containing about 90% w/w or more, such as, e.g., about 92.5% w/w or more, about 95% w/w or more, about 97.5% w/w or more or about 100% of the silica or silica derivative has a tablet hardness of at least about 10 N such as, e.g., at least about 15 N. Again, it is preferred that the tablet contain 100% of the silica or silica derivative.
  • the solid material fulfils all tests.
  • i) has an oil threshold value of at least about 10%, such as, e.g., at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55% or at least about 60%, ii) has a bulk density of from about 15 to about 30 g/100 ml such as, e.g.
  • the solid pharmaceutical material - when tested as described herein - i) has an oil treshold value of at least about 55%;
  • the solid pharmaceutical material - when tested as described herein - ii) releases at least about 75% of an oil; and/or the solid pharmaceutical material - when tested as described herein -
  • iii) in the form of a tablet has disintegration time of at the most about 10 min, when tested according to Ph. Eur. Disintegration test, the tablet containing about 97.5% w/w of the pharmaceutically acceptable material.
  • the solid pharmaceutically acceptable material for use according to the invention is normally a particulate material in the form of e.g. powders, particles, granules, granulates etc.
  • the silica or silica derivative is a granulated fumed silica or silica derivative.
  • the silica or silica derivative is at the most partly present in precipitated form, or the silica or silica derivative is not present in precipitated form.
  • the silica or silica derivative normally has an oil absorption value of at least about 100 g oil/100 g such as, e.g., at least about 150 g oil/100 g, at least about 200 g oil/1 OOg, at least about 250 g oil/100 g, at least about 300 g oil/100 g or at least about 400 g oil/100 g silica or silica derivative.
  • the oil absorption value is determined as described in the experimental section herein.
  • the present inventors have found that a common feature of some of the materials suitable for use as oil sorption material is that they have a relatively large surface area.
  • the silica or silica derivative for use as an oil sorption material according to the invention may have a BET surface area of at least 5 m 2 /g such as, e.g., at least about 25 m 2 /g, at least about 50 m 2 /g, at least about 100 m 2 /g, at least about 150 m 2 /g, at least about 200 m 2 /g, at least about 250 m 2 /g or at least about 275 m 2 /g.
  • a pharmaceutically acceptable material for use as an oil sorption material according to the invention retains a good flowability even if it has been loaded with oil or an oily-like material.
  • the flowability of the pharmaceutically acceptable material loaded with 25% w/w or more such as, e.g. 30% w/w or more, 40% w/w or more, 45% w/w or more, 50% w/w or more, 55% w/w or more, 60% w/w or more, 65% w/w or more or about 70% w/w viscoleo will normally meet the Ph. Eur. requirements.
  • the silica or silica derivative in itself fulfils the test mentioned herein under Threshold Test, but without any addition of viscoleo.
  • the particle size of the silica or silica derivative may according to the invention be selected among wide limits.
  • silicon dioxide materials may be used having median particle sizes in the range of 2-400 ⁇ m, preferably in the range of 5- 250 ⁇ m, more preferred in the range of 10-200 ⁇ m, even more preferred in the range of 10-100 ⁇ m, and most preferred in the range of 20-30 ⁇ m.
  • pharmaceutically acceptable expients that fulfil one or more of the requirements mentioned above can be selected from the group consisting of silica acid or a derivative or salt thereof including silicates, silicon dioxide and polymers thereof; silica silylates, silica dimethylsilylates, magnesium aluminosilicate and/or magnesium aluminometasilicate, bentonite, kaolin, magnesium trisilicate, montmorillonite and/or saponite.
  • the pharmaceutically acceptable material comprises silica acid or a derivative or salt thereof such as, e.g., silicon dioxide or a polymer thereof.
  • the pharmaceutically acceptable material is a silicon dioxide product that has properties corresponding to Aeroperl® such as, Aeroperl® 300 and Aeroperl® R 806/30 (silica silylate) (available from Degussa, Frankfurt, Germany).
  • Aeroperl® such as, Aeroperl® 300 and Aeroperl® R 806/30 (silica silylate) (available from Degussa, Frankfurt, Germany).
  • Aeroperl® 300 (including materials with properties like or corresponding to those of Aeroperl® 300).
  • An oil sorption material according to the invention is very advantageous for use in the preparation of pharmaceutical, cosmetic, nutritional and/or food compositions, wherein the composition comprises oil or an oily-like material.
  • One of the advantages is that is it possible to incorporate a relatively large amount of oil and oily-like material and still have a material that is solid.
  • an oil sorption material according to the invention it is possible to prepare solid compositions with a relatively high load of oil or oily-like materials by use of an oil sorption material according to the invention.
  • the oil sorption material for use in the further processing into solid composition normally absorbs about 5% w/w or more, such as, e.g., about 10% w/w or more, about 15% w/w or more, about 20% w/w or more, about 25% w/w or more, about 30% w/w or more, about 35% w/w or more, about 40% w/w or more, about 45% w/w or more, about 50 w/w or more, about 55% w/w or more, about 60% w/w or more, about 65% w/w or more, about 70% w/w or more, about 75% w/w or more, about 80% w/w or more, about 85% w/w or more, about 90% w/w or more or about 95% w/w or more of an oil or an oily material and is still a solid material.
  • compositions may be in the form of particulate materials, granules, pellets, microspheres, nanoparticles or in the form of oral dosage forms including tablets, sachets, capsules.
  • the oral dosage form is intended for administration via the oral, buccal or sublingual administration route.
  • the invention relates to a solid pharmaceutical particulate material or a pharmaceutical composition
  • a solid pharmaceutical particulate material or a pharmaceutical composition comprising i) an oil or an oily-like material, and ii) a silica or silica derivative as defined herein (oil sorption material),
  • concentration of the oil or oily-like material in the particulate material is about 5% w/w or more such as, e.g., about 10% w/w or more, about 15% w/w or more, about 20% w/w or more, about 25% w/w or more, about 30% w/w or more, about 35% w/w or more, about 40% w/w or more, about 45% w/w or more, about 50 w/w or more, about 55% w/w or more, about 60% w/w or more, about 65% w/w or more, about 70% w/w or more, about 75% w/w or more, about 80% w/w or more, about 85% w/w or more, about 90% w/w or more or about 95% w/w or more.
  • the concentration of the oil or oily-like material in a solid pharmaceutical particulate material or pharmaceutical composition according to the invention is in a range from about 20% to about 80% w/w such as, e.g., from about 25% to about 75% w/w.
  • the invention also relates to a solid pharmaceutical particulate material or a pharmaceutical composition
  • a solid pharmaceutical particulate material or a pharmaceutical composition comprising i) an oil or an oily-like material, ii) a siica or silica derivative as defined herein (oil sorption material),
  • concentration of the pharmaceutically acceptable material in the particulate material is about 5% w/w or more such as, e.g., about 10% w/w or more, about 15% w/w or more, about 20% w/w or more, about 25% w/w or more, about 30% w/w or more, about 35% w/w or more, about 40% w/w or more, about 45% w/w or more, about 50 w/w or more, about 55% w/w or more, about 60% w/w or more, about 65% w/w or more, about 70% w/w or more, about 75% w/w or more, about 80% w/w or more, about 85% w/w or more, about 90% w/w or more or about 95% w/w or more .
  • the concentration of the oil sorption material in a solid pharmaceutical particulate material or a pharmaceutical composition is in a range from about 20% to about 80% w/w such as, e.g., from about 25% to about 75% w/w.
  • the particulate material normally also includes a therapeutically, prophylactically and/or diagnostically active substance.
  • the active substance may be dissolved or dispersed in the oil or oily-like material and be present in the range of 20-75% by weight, preferably in the range of 40-70% by weight, more preferred in the range of 50-70% by weight.
  • the particulate material or composition according to the invention also be coated with a film coating, an enteric coating, a modified release coating, a protective coating, an anti- adhesive coating etc.
  • Suitable coating materials are e.g. methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, acrylic polymers, ethylcellulose, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinylalcohol, sodium carboxymethylcellulose, cellulose acetate, cellulose acetate phthalate, gelatin, methacrylic acid copolymer, polyethylene glycol, shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, zein.
  • Plasticizers and other ingredients may be added in the coating material.
  • the same or different active substance may also be added in the coating material.
  • oils and oily-like materials is used in a very broad sense including oils, waxes, semi-solid materials and materials that normally are used as solvents (such as organic solvents) or cosolvents within the pharmaceutical industry, and the term also includes therapeutically and/or prophylactically active substances that are in liquid form at ambient temperature; furthermore the term includes emulsions like e.g. microemulsions and nanoemulsions and suspensions.
  • the oils and oily-like materials that can be absorbed by a material according the invention will normally be liqiuid at ambient or elevated temperature (for practical reasons the max. temperature is about 250 °C).
  • The may be hydrophilic, lipophilic, hydrophobic and/or amphiphilic materials.
  • oils and oily-like material that are suitable for use in the present context are substances or materials, which have a melting point of at least about 0 °C and at the most about 250 °C.
  • the oil or oily-like material has a melting point of about 5 °C or more such as, e.g., about 10 °C or more, about 15 °C or more, about 20 °C or more or about 25 °C or more.
  • the oil or oily-like material has a melting point of at least about 25 °C such as, e.g., at least about 30 °C at least about 35 °C or at least about 40 °C.
  • the melting point may normally not be too high, thus, the oil or oily-like material normally has a melting point of at the most about 300 °C such as, e.g., at the most about 250 °C, at the most about 200 °C, at the most about 150 °C or at the most about 100 °C. If the melting point is higher a relatively high temperature may promote e.g. oxidation or other kind of degradation of an active substance in those cases where e.g.
  • a therapeutically and/or prophylactically active substance is included.
  • an oil or oily-like material when used the context of pharmaceuticals is intended to denote a pharmaceutically inert material.
  • inert is intended to mean that the material in question does not have any therapeutic activity, i.e. it is not a therapeutically, prophylactically and/or diagnostically active substance.
  • the term normally is intended to mean that the material in question does not participate in any chemical reaction with other constituents such as, e.g., the silica or silica derivatives.
  • the melting point is determined by DSC (Differential Scanning Calorimetry).
  • the melting point is determined as the temperature at which the linear increase of the DSC curve intersects the temperature axis (see Fig. 1 for further details).
  • oils or oily-like materials are generally substances, which are used in the manufacture of pharmaceuticals as so-called melt binders or solid solvents (in the form of solid dosage form), or as co-solvents or ingredients in pharmaceuticals for topical use.
  • hydrophilic, hydrophobic and/or have surface-active properties It may be hydrophilic, hydrophobic and/or have surface-active properties.
  • hydrophilic and/or hydrophobic oils or oily-like materials are suitable for use in the manufacture of a pharmaceutical composition comprising a therapeutically and/or prophylactically active substance that has a relatively low aqueous solubility and/or when the release of the active substance from the pharmaceutical composition is designed to be immediate or non-modified.
  • Hydrophobic oil or oily-like materials are normally used in the manufacture of a modified release pharmaceutical composition.
  • a suitable hydrophilic oil or oily-like material is selected from the group consisting of: polyether glycols such as, e.g., polyethylene glycols, polypropylene glycols; polyoxyethylenes; polyoxypropylenes; poloxamers and mixtures thereof, or it may be selected from the group consisting of: xylitol, sorbitol, potassiunrrsodium tartrate, sucrose tribehenate, glucose, rhamnose, lactitol, behenic acid, hydroquinon monomethyl ether, sodium acetate, ethyl fumarate, myristic acid, citric acid, Gelucire 50/13, other Gelucire types such as, e.g., Gelucire 44/14 etc., Gelucire 50/10, Gelucire 62/05, Sucro-ester 7, Sucro-ester 11, Sucro-ester 15, maltose, mannitol and mixtures thereof.
  • polyether glycols such as, e.g.
  • a suitable hydrophobic oil or oily-like material may be selected from the group consisting of: straight chain saturated hydrocarbons, sorbitan esters, paraffins; fats and oils such as e.g., cacao butter, beef tallow, lard, polyether glycol esters; higher fatty acid such as, e.g.
  • stearic acid myristic acid, palmitic acid, higher alcohols such as, e.g., cetanol, stearyl alcohol, low melting point waxes such as, e.g., glyceryl monostearate, hydrogenated tallow, myristyl alcohol, stearyl alcohol, substituted and/or unsubstituted monoglycerides, substituted and/or unsubstituted diglycerides, substituted and/or unsubstituted triglycerides, yellow beeswax, white beeswax, carnauba wax, castor wax, japan wax, acetylate monoglycerides; NVP polymers, PVP polymers, acrylic polymers, or a mixture thereof.
  • alcohols such as, e.g., cetanol, stearyl alcohol, low melting point waxes such as, e.g., glyceryl monostearate, hydrogenated tallow, myristyl
  • the oil or oily-like material is a polyethylene glycol having an average molecular weight in a range of from about 400 to about 35,000 such as, e.g., from about 800 to about 35,000, from about 1 ,000 to about 35,000 such as, e.g., polyethylene glycol 1 ,000, polyethylene glycol 2,000, polyethylene glycol 3,000, polyethylene glycol 4,000, polyethylene glycol 5,000, polyethylene glycol 6000, polyethylene glycol 7,000, polyethylene glycol 8,000, polyethylene glycol 9,000 polyethylene glycol 10,000, polyethylene glycol 15,000, polyethylene glycol 20,000, or polyethylene glycol 35,000.
  • polyethylene glycol may be employed with a molecular weight from about 35,000 to about 100,000.
  • the oil or oily-like material is polyethylene oxide having a molecular weight of from about 2,000 to about 7,000,000 such as, e.g. from about 2,000 to about 100,000, from about 5,000 to about 75,000, from about 10,000 to about 60,000, from about 15,000 to about 50,000, from about 20,000 to about 40,000, from about 100,000 to about 7,000,000 such as, e.g., from about 100,000 to about 1 ,000,000, from about 100,000 to about 600,000, from about 100,000 to about 400,000 or from about 100,000 to about 300,000.
  • the oil or oily-like material is a poloxamer such as, e.g. Poloxamer 188, Poloxamer 237, Poloxamer 338 or Poloxamer 407 or other block copolymers of ethylene oxide and propylene oxide such as the Pluronic® and/or Tetronic® series.
  • Suitable block copolymers of the Pluronic® series include polymers having a molecular weight of about 3,000 or more such as, e.g. from about 4,000 to about 20,000 and/or a viscosity (Brookfield) from about 200 to about 4,000 cps such as, e.g., from about 250 to about 3,000 cps.
  • Suitable examples include Pluronic® F38, P65, P68LF, P75, F77, P84, P85, F87, F88, F98, P103, P104, P105, F108, P123, F123, F127, 10R8, 17R8, 25R5, 25R8 etc.
  • Suitable block copolymers of the Tetronic® series include polymers having a molecular weight of about 8,000 or more such as, e.g., from about 9,000 to about 35,000 and/or a viscosity (Brookfield) of from about 500 to about 45,000 cps such as, e.g., from about 600 to about 40,000. The viscosities given above are determined at 60 °C for substances that are pastes at room temperature and at 77 °C for substances that are solids at room temperature.
  • the oil or oily-like material may also be a sorbitan ester such as, e.g., sorbitan di- isostearate, sorbitan dioleate, sorbitan monolaurate, sorbitan monoisostearate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesqui-isostearate, sorbitan sesquioleate, sorbitan sesquistearate, sorbitan tri-isostearate, sorbitan trioleate, sorbitan tristearate or mixtures thereof.
  • sorbitan ester such as, e.g., sorbitan di- isostearate, sorbitan dioleate, sorbitan monolaurate, sorbitan monoisostearate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesqui-isostearate, sorb
  • the oil or oily-like material may of course comprise a mixture of different oils or oily-like materials such as, e.g., a mixture of hydrophilic and/or hydrophobic materials.
  • oils or oily-like materials may be solvents or semi-solid excipients like, e.g. propylene glycol, polyglycolised glycerides including Gelucire 44/14, complex fatty materials of plant origin including theobroma oil, carnauba wax, vegetable oils like e.g. almond oil, coconut oil, corn oil, cottonseed oil, sesame oil, soya oil, olive oil, castor oil, palm kernels oil, peanut oil, rape oil, grape seed oil etc., hydrogenated vegetable oils such as, e.g.
  • a solid pharmaceutical particulate material or a pharmaceutical composition according to the invention may further comprise a pharmaceutically acceptable excipient.
  • pharmaceutically acceptable excipient are intended to denote any material, which is inert in the sense that it substantially does not have any therapeutic and/or prophylactic effect per se. Such an excipient may be added with the purpose of making it possible to obtain a pharmaceutical, cosmetic and/or foodstuff composition, which have acceptable technical properties.
  • excipients for use a particular material or composition according to the invention include fillers, diluents, disintegrants, binders, lubricants etc. or mixture thereof.
  • the choice of excipients is normally made taken such different uses into considerations.
  • Other pharmaceutically acceptable excipients for suitable use are e.g. acidifying agents, alkalizing agents, preservatives, antioxidants, buffering agents, chelating agents, coloring agents, complexing agents, emulsifying and/or solubilizing agents, flavors and perfumes, humectants, sweetening agents, wetting agents etc.
  • suitable fillers, diluents and/or binders include lactose (e.g. spray-dried lactose, ⁇ -lactose, Mactose, Tabletose®, various grades of Pharmatose®, Microtose® or Fast-Floe®), microcrystalline cellulose (various grades of Avicel®, Elcema®, Vivacel®, Ming Tai® or Solka-Floc®), hydroxypropylcellulose, L-hydroxypropylcellulose (low substituted), hydroxypropyl methylcellulose (HPMC) (e.g. Methocel E, F and K, Metolose SH of Shin-Etsu, Ltd, such as, e.g.
  • lactose e.g. spray-dried lactose, ⁇ -lactose, Mactose, Tabletose®, various grades of Pharmatose®, Microtose® or Fast-Floe®
  • microcrystalline cellulose variant grades of Avicel®, Elce
  • methylcellulose polymers such as, e.g., Methocel A, Methocel A4C, Methocel A15C, Methocel A4M), hydroxyethylcellulose, sodium carboxymethylcellulose, carboxymethylene, carboxymethylhydroxyethylcellulose and other cellulose derivatives, sucrose, agarose, sorbitol, mannitol, dextrins, maltodextrins, starches or modified starches (including potato starch, maize starch and rice starch), calcium phosphate (e.g.
  • diluents are e.g. calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrans, dextrin, dextrose, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose, sugar etc.
  • disintegrants are e.g. alginic acid or alginates, microcrystalline cellulose, hydroxypropyl cellulose and other cellulose derivatives, croscarmellose sodium, crospovidone, polacrillin potassium, sodium starch glycolate, starch, pregelatinized starch, carboxymethyl starch (e.g. Primogel® and Explotab®) etc.
  • binders are e.g. acacia, alginic acid, agar, calcium carrageenan, sodium carboxymethylcellulose, microcrystalline cellulose, dextrin, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxypropyl methylcellulose, methylcellulose, pectin, PEG, povidone, pregelatinized starch etc.
  • Glidants and lubricants may also be included in the second composition.
  • examples include stearic acid, magnesium stearate, calcium stearate or other metallic stearate, talc, waxes and glycerides, light mineral oil, PEG, glyceryl behenate, colloidal silica, hydrogenated vegetable oils, corn starch, sodium stearyl fumarate, polyethylene glycols, alkyl sulfates, sodium benzoate, sodium acetate etc.
  • excipients which may be included in the particulate material or composition are e.g. flavoring agents, coloring agents, taste-masking agents, pH-adjusting agents, buffering agents, preservatives, stabilizing agents, anti-oxidants, wetting agents, humidity-adjusting agents, surface-active agents, suspending agents, absorption enhancing agents, agents for modified release etc.
  • additives in a particulate material or in a composition according to the invention may be antioxidants like e.g. ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, potassium metabisulfite, propyl gallate, sodium formaldehylde sulfoxylate, sodium metabisulfite, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherol acetate, tocopherol hemisuccinate, TPGS or other tocopherol derivatives, etc.
  • the carrier composition may also contain e.g. stabilising agents.
  • the concentration of an antioxidant and/or a stabilizing agent in the carrier composition is normally from about 0.1 % w/w to about 5% w/w. Active substances
  • a solid pharmaceutical particulate material or a composition according to the invention may further comprise a therapeutically, prophylactically and/or diagnostically active substance.
  • a particulate material or composition according to the invention comprises a therapeutically and/or prophylactically active substance.
  • the particulate matter or composition may also or alternatively comprise a cosmetically active substance (i.e. a substance that is employed in cosmetic compositions).
  • a therapeutically and/or prophylactically active substance includes any biologically and/or physiologically active substance that has a function on an animal such as, e.g. a mammal like a human.
  • the term includes drug substances, hormones, genes or gene sequences, antigen- comprising material, proteins, peptides, nutrients like e.g. vitamins, minerals, lipids and carbohydrates and mixtures thereof.
  • the term includes substances that have utility in the treatment and/or preventing of diseases or disorders affecting animals or humans, or in the regulation of any animal or human physiological condition.
  • the term also includes any biologically active substance which, when administered in an effective amount, has an effect on living cells or organisms.
  • active substances suitable for use in a particulate material or composition according to the invention are in principle any active substance such as, e.g. freely water soluble as well as more slightly or insoluble active substances.
  • active substances suitable for use are e.g.
  • antibacterial substances antihistamines and decongestants, anti-inflammatory agents, antiparasitics, antivirals, local anesthetics, antifungals, amoebicidals or trichomonocidal agents, analgesics, antianxiety agents, anticlotting agents, antiarthritics, antiasthmatics, antiarthritic, anticoagulants, anticonvulsants, antidepressants, antidiabetics, antiglaucoma agents, antimalarials, antimicrobials, antineoplastics, antiobesity agents, antipsychotics, antihypertensives, antitussives, auto-immune disorder agents, anti-impotence agents, anti-Parkinsonism agents, anti-Alzheimers' agents, antipyretics, anticholinergics, anti-ulcer agents, anorexic, beta-blockers, beta-2 agonists, beta agonists, blood glucose-lowering agents, bronchodilators, agents with effect on the central nervous
  • Anti-inflammatory drugs like e.g. ibuprofen, indometacin, naproxen, nalophine;
  • Anti-Parkinsonism agents like e.g. bromocriptine, biperidin, benzhexol, benztropine etc.
  • Antidepressants like e.g. imipramine, nortriptyline, pritiptyline, etc.
  • Antibiotics like e.g. clindamycin, erythomycin, fusidic acid, gentamicin, mupirocine, amfomycin, neomycin, metronidazol, sulphamethizole, bacitracin, framycetin, polymyxin B, acitromycin etc,
  • Antifungal agents like e.g. miconazol, ketoconaxole, clotrimazole, amphotericin B, nystatin, mepyramin, econazol, fluconazol, flucytocine, griseofulvin, bifonazole, amorofine, mycostatin, itraconazole, terbenafine, terconazole, tolnaftate etc.
  • Antimicrobial agents like e.g.melronida ole, telracyclines, o ytetracylines, peniciilins etc.
  • Antiemetics like e.g. metoclopramide, droperidol, haloperidol, promethazine etc.
  • Antihistamines like e.g. chlorpheniramine, terfenadine, triprolidine etc.
  • Antimigraine agents like e.g. dihydroergotamine, ergotamine, pizofylline etc.
  • Coronary, cerebral or peripheral vasodilators like e.g. nifedipine, diltiazem etc.
  • Antianginals such as, e.g., glyceryl nitrate, isosorbide dinitrate, molsidomine, verapamil etc.
  • Calcium channel blockers like e.g. verapamil, nifedipine, diltiazem, nicardipine etc.
  • Hormonal agents like e.g. estradiol, estron, estriol, polyestradiol, polyestriol, dienestrol, diethylstilbestrol, progesterone, dihydroprogesterone, cyprosterone, danazol, testosterone etc.
  • Contraceptive agents like e.g. ethinyl estradiol, lynestrenol, etynodiol, norethisterone, mestranol, norgestrel, levonorgestrel, desodestrel, medroxyprogesterone etc.
  • Antithrombotic agents like e.g. heparin, warfarin etc.
  • Diuretics like e.g. hydrochlorothiazide, flunarizine, minoxidil etc.
  • Antihypertensive agents like e.g. propanolol, metoprolol, clonidine, pindolol etc.
  • Corticosteroids like e.g. beclomethasone, betamethasone, betamethasone-17-valerate, betamethasone-dipropionate, clobetasol, clobetasol- 17-butyrate, clobetasol-propionate, desonide, desoxymethasone, dexamethasone, diflucortolone, flumethasone, flumethasone-pivalte, fluocinolone acetonide, fluocinoide, hydrocortisone, hydrocortisone- 17-butyrate, hydrocortisonebuteprate,methylprednisolone, triamcinolone acetonide, hacinonide, fluprednide acetate, alklometasone-dipropionate, fluocortolone, fluticason- propionte, mometasone-furate, desoxymethasone, diflurason-diacetate, halquinol
  • Dermatological agents like e.g. nitrofurantoin, dithranol, clioquinol, hydroxyquinoline, isotretionin, methoxsalen, methotrexate, tretionin, trioxalen, salicylic acid, penicillamine etc.
  • Steroids like e.g. estradiol, progesterone, norethindrone, levonorgestrel, ethynodiol, levonorgestrol, norgestimate, gestanin, desogestrel, 3-keton-desogesterel, demegestone, promethoestrol, testosterone, spironolactone and esters thereof etc.
  • Nitro compounds like e.g. amyl nitrates, nitroglycerine and isosorbide nitrate etc.
  • Opioids like e.g. morphine, buprenorphine, oxymorphone, hydromorphone, codeine, tramadol etc.
  • Prostaglandins such as, e.g., a member of the PGA, PGB, PGE or PGF series such as, e.g. minoprostol, dinoproston, carboprost, eneprostil etc.
  • Peptides like e.g. growth hormone releasing factors, growth factors (e.g.
  • epidermal growth factor EGF
  • nerve growth factor NGF
  • TGF TGF
  • PDGF insulin growth factor
  • IGF insulin growth factor
  • aFGF fibroblast growth factor
  • somatostatin calcitonin
  • insulin vasopressin
  • interferons IL-2 etc.
  • urokinase serratiopeptidase
  • superoxide dismutase thyrotropin releasing hormone
  • lutenizing hormone releasing hormone LH-RH
  • corticotrophin releasing hormone growth hormone releasing hormone (GHRH)
  • GHRH growth hormone releasing hormone
  • EPO colony stimulating factor
  • CSF colony stimulating factor
  • Urinary disorder agents Harnal® Proscar® Cardura® Flomax® Detrol®
  • the amount of active substance incorporated in a particulate material may be selected according to known principles of pharmaceutical formulation.
  • the dosage of the active substance present in a particulate material according to the invention depends inter alia on the specific drug substance, the age and condition of the patient and of the disease to be treated.
  • the therapeutically, prophylactically and/or diagnostically active substance is solid at ambient temperature. It may also at least partly, including totally, be present in the form of a solid dispersion including a solid solution. In the latter case, the active substance may be dispersed or dissolved in the oil or oily-like material.
  • a particulate material or composition according to the invention may comprise a cosmetically active ingredient and/or a food ingredient.
  • a cosmetically active ingredient and/or a food ingredient.
  • Specific examples include vitamins, minerals, vegetable oils, hydrogenated vegetable oils, etc.
  • the invention also relates to a method for the preparation of a pharmaceutical composition
  • a pharmaceutical composition comprising about 5% w/w or more such as, e.g., about 10% w/w or more, about 15% w/w or more, about 20% w/w or more, about 25% w/w or more, about 30% w/w or more, about 35% w/w or more, about 40% w/w or more, about 45% w/w or more, about 50 w/w or more, about 55% w/w or more, about 60% w/w or more, about 65% w/w or more, about 70% w/w or more, about 75% w/w or more, about 80% w/w or more, about 85% w/w or more, about 90% w/w or more or about 95% w/w or more of an oil or an oily- like material, the method comprising loading the oil or oily-like material to a pharmaceutically acceptable material defined herein (oil sorption material).
  • agglomerates according to the invention may be prepared using procedures known within the area for melt agglomeration.
  • Examplary of apparatus which may be used are low shear mixers, high shear mixers, fluid beds, fluid bed granulators, rotary fluidised beds and drum granulators.
  • the agglomerate is prepared by melting the oil or oily-like material, dissolving or dispersing the active compound in the melt, and spraying or pouring the melt on the silica or silica derivative.
  • the spraying or pouring step may be performed in accordance with known procedures.
  • all constituents of the agglomerate is added to a high shear mixer, optionally provided with a heating jacket.
  • a high shear mixer By operating the high shear mixer the friction heat and heat supplied by the heating jacket will melt the vehicle, which subsequently dissolve or disperse the active compound and deposits at a composition comprising the silica or silica derivative.
  • the loading of the oil sorption material with oil or oily-like material is normally performed by mixing (e.g. mechanically or in fluid-bed or in a spray drier), spraying and/or pouring such as by melt agglomeration or controlled agglomeration techniques.
  • the controlled agglomeration is performed by i) spraying a first composition in liquid form comprising an oil or an oily-like material on a second composition in solid form comprising a silica or silica derivative as defined in any of claims 1-30, and ii) mixing or other means of mechanical working the second composition onto which the first composition is sprayed to obtain a pharmaceutical particulate material, which optionally may be further processed to obtain a pharmaceutical dosage form.
  • the prepared agglomerate may be influenced by several process variables such as temperature of vehicle, filler and heating jacket; the impeller speed, time of treatment etc.
  • process variables such as temperature of vehicle, filler and heating jacket; the impeller speed, time of treatment etc.
  • the skilled person can using simple routine experiments determine suitable parameters for an intended melt agglomeration process using a given active compound, filler and vehicle, with use of a particular given suitable equipment.
  • the particulate material in the form of agglomerates according to the invention may be used for the preparation of pharmaceutical compositions for oral administration according to well known procedures.
  • Pharmaceutical compositions may be prepared by mixing a agglomerate with usual pharmaceutical acceptable excipients, followed by preparing the composition using said mixture.
  • Preferred pharmaceutical composition for oral administration according to the invention are tablets and capsules.
  • Tablets may be prepared using procedures known as such, such as mixing the agglomerate according to the invention with known excipients usually used for tablets, and pressing the resulting mixture into tablets.
  • the tablets may or may not be coated according to well known procedures.
  • Capsules may be prepared using procedures know as such, for example mixing a agglomerate according to the invention with suitable excipients, and filling the mixture into suitable capsules, such as gelatine capsules.
  • a pharmaceutical composition is prepared using a particular material, an agglomerate, according to the invention comprising an active compound and a water soluble oil or oily-like material.
  • the pharmaceutical composition will provide the active compound for fast and high bioavailability of the active compound after ingestion of the pharmaceutical composition.
  • a pharmaceutical composition is prepared using a particulate material, an agglomerate, according to the invention comprising an active compound and a vehicle insoluble in water.
  • the pharmaceutical composition will provide a sustained release of the active compound over a prolonged period of time.
  • a pharmaceutical composition comprising two or more different agglomerates.
  • These two or more agglomerates may comprise same active compound but different vehicles, thus providing differing release rates of the active compound from the two or more agglomerates, in order to provide pharmaceutical having a particular desired release profile of the active compound.
  • the two or more agglomerates may comprise different active compounds. The skilled person will appreciate that other combinations may be used for providing for a particular desired effect.
  • the test involves determination of flowability according to the method described in Ph. Eur. by measuring the flow rate of the material out of a funnel with a nozzle diameter of 10.0 mm.
  • Viscoleo (medium chain triglycerides MCT; Miglyol 812 N from Condea) was added to 100 g of the solid pharmaceutically acceptable material to be tested for use according to the invention and mixed manually. The mixture obtained was sieved through sieve 0.3 mm to assure a homogenous mixture. The oil was added successively until a flow of 100 g of the mixture could not flow through the nozzle. If the material to be tested has a high bulk volume (e.g. like that of Aeroperl 300) only 50 g of the mixture is used when testing these blends. The maximal concentration of oil where flow of material could be obtained is called the Threshold Value (given as % w/w).
  • the disintegration time was determined according to the method described in to Ph. Eur.
  • the bulk density was measured by pouring 100 g of the powder in question in a 250 ml graduated cylinder. The bulk density is given as the tapped bulk density in g/ml. The determination was performed according to Ph. Eur. (apparent volume).
  • the oil absorption value is determined by adding well-defined amounts (a 10 g) of viscoleo to a well-defined amount of the pharmaceutically acceptable material (100 g) to be tested.
  • the oil absorption value (expressed as g viscoleo/100 g material) is reached when a further addition of 10 g oil results in a material that does not have suitable properties with respect to flowability, i.e. the material does not meet the meet the requirements when tested according to Ph. Eur. (flowability test; see above under Threshold Test herein).
  • the apparatus applied was a Micromertics Gemini 2375.
  • the method applied was according to USP volumetric methods based on multiple point determination.
  • the flowability was determined according to the method described in Ph. Eur. measuring the flow rate of the material out of a funnel with a nozzle diameter of 10.0 mm.
  • the tablets prepared in the Examples herein were subject to at test for tablet hardness employing Schleuniger Model 6D apparatus and performed in accordance with the general instructions for the apparatus.
  • the flowability was determined according to the method described in Ph. Eur. measuring the flow rate of the material out of a funnel with a nozzle diameter of 10.0 mm.
  • Viscoleo was added to 100 g of the solid material and mixed manually. The material was sieved through sieve 0.3 mm to assure a homogenous mixture. The oil was added successively until a flow of 100 g of the mixture could not flow thorugh the nozzle. Due to the high bulk volume of Aeroperl only 50 g of the mixture was used when testing these blends. The maximal concentration of oil where flow of material could be obtained is shown in Table 2.
  • Particulate materials such as Aeroperl and Neusilin having a very high specific surface area, BET surface area, (200-300 m 2 /g) are able to absorb high amounts of liquid vehicles without loosing flowability as compared to commonly used free flowing tablet fillers such as Di-cafos or lactose.
  • Circular tablet of 8 mm in diameter was manually compressed on an excentric tabletting machine, TM20, Diaf.
  • the tablets only contained Aeroperl 300 and Neusilin, respectively.
  • the disintegration time was measured according to the procedure in Ph. Eur. and the tablet hardness was estimated using Schleuniger 6D. The results are shown in Table 3.
  • the melt (Gelucire 44/14) was heated to 70 °C and sprayed on 100 g Aeroperl 300 keeping the product temperature below 35 °C during processing.
  • the amount of Gelucire applied to Aeroperl corresponded to 72% of total (261 g Gelucire applied to 100 g Aeroperl).
  • the agglomerated product was mixed with Avicel PH200 in a Turbula mixer and tabletted without addition of glidant. Subsequently the blend was compressed on an excentric tabletting machine Diaf TM20. Tablet diameter was 8 mm (compound cup). The tablet characteristics are shown in Table 4.
  • Disintegration time and tablet weight variation is determined according to Ph. Eur.
  • the tablet hardness is determined on a Schleuniger 6D.
  • the load of Gelucire could be significantly increased (65-75% the load was about 68%) using Aeroperl 300 compared to other conventional fillers.
  • Addition of Avicel as extra granular phase resulted in increasing tablet hardness positively correlated to the concentration of Avicel.
  • the results also show that it is possible to compress tablets from the material obtained by loading Gelucire on Aeroperl 300 without addition of any excipients.
  • Aeropearl 300 and different qualities of Sipernat are measured through a 10 mm nozzle (PhEur). 100 ml material is used for each measurement.
  • Bulk density is measured by weighing 100 ml material gently added in a measuring cylinder.
  • Sipernat 50 and 50 S differ from Aeroperl in having a lower bulk density g/ml and poor flowability. Further, tablet compression was not possible or resulted in tablets with very low hardness. Accordingly, the Sipernat qualities are not suitable for use according to the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation de silice ou d'un dérivé de silice tel, par exemple, Aeroperl® en tant que matériau de sorption pour les huiles ou les matières huileuses. La silice ou le dérivé de silice peut être chargée d'une quantité relativement élevée d'huile ou de matière huileuse et cette capacité est notamment utile pour la formulation de compositions pharmaceutiques comprenant une substance médicamenteuse présentant des problèmes de biodisponibilité et/ou d'hydrosolubilité par exemple. De plus, la silice ou le dérivé de silice peut libérer l'huile ou la matière huileuse lorsqu'elle/il est mis(e) en contact avec un milieu aqueux et/ou présente des propriétés de comprimé convenables.
EP04711988A 2003-02-19 2004-02-18 Utilisation de silice ou d'un derive de silice en tant que materiau de sorption Withdrawn EP1601347A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300252 2003-02-19
DK200300252 2003-02-19
DKPA200301013 2003-07-03
DK200301013 2003-07-03
PCT/DK2004/000112 WO2004073689A1 (fr) 2003-02-19 2004-02-18 Utilisation de silice ou d'un derive de silice en tant que materiau de sorption

Publications (1)

Publication Number Publication Date
EP1601347A1 true EP1601347A1 (fr) 2005-12-07

Family

ID=32910022

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04711988A Withdrawn EP1601347A1 (fr) 2003-02-19 2004-02-18 Utilisation de silice ou d'un derive de silice en tant que materiau de sorption

Country Status (3)

Country Link
EP (1) EP1601347A1 (fr)
CA (1) CA2516096A1 (fr)
WO (1) WO2004073689A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122482A1 (en) * 2003-10-03 2007-05-31 Per Holm Method for preparing modified release pharmaceutical compositions
CA2540984C (fr) 2003-10-10 2011-02-08 Lifecycle Pharma A/S Forme de dose solide comprenant un fibrate
CA2541382A1 (fr) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S Forme posologique solide comprenant une fibrate et une statine
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050153976A1 (en) * 2003-12-17 2005-07-14 Schering Corporation Pharmaceutical compositions
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
FR2876028B1 (fr) * 2004-10-05 2009-10-16 Axiss France Sas Encapsulation d'extraits vegetaux
ES2289923B1 (es) * 2006-04-03 2008-11-01 Carotenoid Technologies S.A. Preparacion a base de extractos vegetales para alimentacion animal.
DE202008018063U1 (de) * 2007-04-25 2011-10-11 Teva Pharmaceutical Industries Ltd. Pharmazeutischer Hilfsstoffkomplex
ES2553897T3 (es) 2008-05-02 2015-12-14 Gilead Sciences, Inc. El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico
MX344642B (es) 2009-12-29 2017-01-04 W R Grace & Co -Conn * Composiciones para formar peliculas que tienen un grado deseado de cobertura y metodos para hacer y usar las mismas.
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물
JP6513031B2 (ja) * 2013-02-01 2019-05-15 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 液体テクノロジーのための担体としての多孔質シリカゲル
IL225825A (en) 2013-04-18 2014-06-30 Nobactra Israel Ltd Kit and methods for the treatment or prevention of plant pathogenic infection and several isolated antagonistic missiles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037379A1 (fr) * 2001-10-30 2003-05-08 Degussa Ag Utlisation de materiaux granuleux a base de dioxyde de silicium produit de façon pyrogenique dans des compositions pharmaceutiques
WO2004073687A1 (fr) * 2003-02-19 2004-09-02 H. Lundbeck A/S Procede de preparation d'un agglomere par agglomeration a chaud

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US4603143A (en) * 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) * 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2631620B1 (fr) * 1988-05-19 1990-07-27 Rhone Poulenc Chimie Nouvelle silice precipitee absorbante et composition a base de cette s ilice
FR2767071B1 (fr) * 1997-08-06 1999-09-10 Rhodia Chimie Sa Composition comprenant un liquide absorbe sur un support a base de silice precipitee
JP4027535B2 (ja) * 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
DE10112651A1 (de) * 2001-03-16 2002-09-19 Degussa Inhomogene Kieselsäuren als Trägermaterial
CN100579514C (zh) * 2001-07-06 2010-01-13 生命周期药物公司 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037379A1 (fr) * 2001-10-30 2003-05-08 Degussa Ag Utlisation de materiaux granuleux a base de dioxyde de silicium produit de façon pyrogenique dans des compositions pharmaceutiques
WO2004073687A1 (fr) * 2003-02-19 2004-09-02 H. Lundbeck A/S Procede de preparation d'un agglomere par agglomeration a chaud

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004073689A1 *

Also Published As

Publication number Publication date
CA2516096A1 (fr) 2004-09-02
WO2004073689A1 (fr) 2004-09-02

Similar Documents

Publication Publication Date Title
AU2005256322B2 (en) Porous tablets as carriers for liquid formulations
AU2007203715B2 (en) Disintegrating loadable tablets
US20070122482A1 (en) Method for preparing modified release pharmaceutical compositions
US8535799B2 (en) Controlled agglomeration
AU2002325192A1 (en) Controlled agglomeration
EP1601347A1 (fr) Utilisation de silice ou d'un derive de silice en tant que materiau de sorption
WO2004062643A1 (fr) Dispersions seches
CN1758901B (zh) 硅石或硅石衍生物作为吸附材料的用途
MXPA06014888A (es) Metodos para modular actividad celular que involucra esfingosina cinasa y agentes para los mismos, y variantes de esfingosina cinasa.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VELOXIS PHARMACEUTICALS A/S

17Q First examination report despatched

Effective date: 20110902

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120313